Table 1 Patient demographics and characteristics.
Parameter | Serum biomarker analysis set | Full analysis set (N = 153) | ||
|---|---|---|---|---|
LEN + EVE (n = 49) | LEN (n = 51) | EVE (n = 47) | ||
Median age, years (range) | 61.0 (44, 79) | 64.0 (41, 79) | 58.0 (37, 77) | 61.0 (37, 79) |
Males, n (%) | 33 (67.3) | 38 (74.5) | 35 (74.5) | 112 (73.2) |
ECOG PS, n (%) | ||||
0 | 26 (53.1) | 28 (54.9) | 27 (57.4) | 84 (54.9) |
1 | 23 (46.9) | 23 (45.1) | 20 (42.6) | 69 (45.1) |
MSKCC risk group, n (%)a | ||||
Favourable | 11 (22.4) | 11 (21.6) | 12 (25.5) | 35 (22.9) |
Intermediate | 19 (38.8) | 17 (33.3) | 18 (38.3) | 56 (36.6) |
Poor | 19 (38.8) | 23 (45.1) | 17 (36.2) | 62 (40.5) |
IMDC risk group, n (%) | ||||
Favourable | 7 (14.6) | 7 (13.7) | 9 (19.1) | 24 (15.8) |
Intermediate | 31 (64.6) | 32 (62.7) | 27 (57.4) | 94 (61.8) |
Poor | 10 (20.8) | 12 (23.5) | 11 (23.4) | 34 (22.4) |
Median duration of most recent prior VEGF-targeted therapy, months, months (range) | 9.6 (2.0, 66.2) | 13.5 (0.7, 81.8) | 8.8 (1.6, 57.8) | 11.5 (0.7, 81.8) |
